SunRISe-2 (BLC3001)
29 Nov 2021
Trial Summary
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.
Acronym:
SunRISe-2
ACTRN/NCT /ethics:
NCT04658862
Scientific title:
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
Sponsor / Cooperative group:
Janssen Research & Development, LLC
Trial & Patient Characteristics
| Cancer Type | Bladder |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2020-12-07 |
| Anticipated End Date | 2026-12-26 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Hannah Adelson |
| Hannah.adelson@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Sina Vatandoust |
| Recruitment Status | Recruiting |